Inventor · disambiguated record
Masanori Kato
Also filed as: KATO MASANORI
8 granted patents·3 pending applications·9 citations·filing 2007–2021
78Inventor score
Top patents by PatentIndex Score
11 records- 0193US10155768B2Fused pyrimidine compound or salt thereofTAIHO PHARMACEUTICAL CO LTD·Filed 2017·Granted Dec 18, 2018·8 cites·9 claims
- 0275US10233189B2Fused pyrimidine compound or salt thereofTAIHO PHARMACEUTICAL CO LTD·Filed 2017·Granted Mar 19, 2019·1 cites·20 claims
- 0371US10787457B2Fused pyrimidine compound or salt thereofTAIHO PHARMACEUTICAL CO LTD·Filed 2018·Granted Sep 29, 2020·0 cites·3 claims
- 0469US11014930B2Fused pyrimidine compound or salt thereofTAIHO PHARMACEUTICAL CO LTD·Filed 2020·Granted May 25, 2021·0 cites·21 claims
- 0568US11236096B2Fused pyrimidine compound or salt thereofTAIHO PHARMACEUTICAL CO LTD·Filed 2020·Granted Feb 1, 2022·0 cites·8 claims
- 0665US11046696B2Fused pyrimidine compound or salt thereofTAIHO PHARMACEUTICAL CO LTD·Filed 2020·Granted Jun 29, 2021·0 cites·7 claims
- 0763US10807986B2Fused pyrimidine compound or salt thereofTAIHO PHARMACEUTICAL CO LTD·Filed 2018·Granted Oct 20, 2020·0 cites·7 claims
- 0863US2008138326A1Method for cancer treatment, carcinogenesis suppression or mitigation of adverse reactions of anticancer agentsKANEKA CORP·Filed 2007·Application pending·0 cites
- 0956US2024000791A1Methods of Using 4-Amino-N-[4-(Methoxymethyl)Phenyl]-7-(1-Methylcyclopropyl)-6-(3-Morpholinoprop-1-YN-1-YL)-7H-Pyrrolo[2,3-D]Pyrimidine-5-Carboxamide for the Treatment of TumorsHELSINN HEALTHCARE SA·Filed 2021·Application pending·0 cites
- 1041US10729737B2Muscle-enhancing agentKANEKA CORP·Filed 2016·Granted Aug 4, 2020·0 cites·12 claims
- 1141US2014378409A1Effect potentiator for antitumor agentsTAIHO PHARMACEUTICAL CO LTD·Filed 2012·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Masanori Kato files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →